Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 16

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
4 9,694,152

On
September 18, 2024 the Board of Directors of Regen Biopharma, Inc.(“ Regen”) declared a dividend to all shareholders of record
as of October 17,2024 (“ Record Date”) be paid to shareholders on November 1, 2024 such dividend to be payable in shares of
the Regen’s authorized but unissued Common Stock and to consist of one share of Common Stock for every one share of Regen Biopharma,
Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record
Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as
of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date.

On
November 1, 2024 15,426,385 15,426,385

On
November 4, 2024 the Company issued 500,000 20,000

On
November 13, 2024 the Company issued 370,084

10. RELATED PARTY TRANSACTIONS

On
June 23, 2015 the Company entered into an agreement (“ Agreement”) with Zander Therapeutics, Inc. (“ Zander”) whereby
The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual
property controlled by The Company (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years.
Zander is under common control with the Company.

Pursuant
to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000)
as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand
US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The
abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant
to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales, as such term is defined in
the Agreement, of any Licensed Products, as such term